从最新循证证据看左洛复临床治疗地位详解.pptVIP

* Now let’s turn to the ziprasidone data. An analysis of several short-term and long-term active or placebo-controlled schizophrenia studies found that ziprasidone has a relatively favorable weight profile in both the short-term and long-term.1 Additional Information1: Ziprasidone Short-term Studies An analysis of several ziprasidone short-term active or placebo-controlled studies: The incidence of clinically relevant (7%) weight gain with ziprasidone (9.1%) was comparable to that observed with haloperidol (9.6%) The incidence of clinically relevant (7%) weight loss with ziprasidone was low (4.2%) and comparable to that seen with haloperidol (5.2%) and placebo (3.2%) There was no evidence of either a dose or gender effect on mean weight change in these studies By contrast, the incidence of weight gain 7% with olanzapine (48%), risperidone (17%), and amisulpride (16%) showed statistical significance compared with placebo The majority of patients on ziprasidone had no clinically relevant weight change (data not shown) Ziprasidone Long-term Studies An analysis of several ziprasidone long-term (6 to 30 months) active or placebo-controlled studies: At 1 year, 28% of patients experienced 7% weight loss, while only 15% experienced 7% weight gain. Weight loss was also more common with placebo The incidence of clinically relevant (7%) weight gain with ziprasidone (15%) was half that observed with haloperidol (33%) and not more clinically relevant than that observed with placebo (10%) There was no evidence of either a dose or gender effect on mean weight change in these studies By contrast, the incidence of clinically relevant weight gain 7% with olanzapine (53%) and risperidone (38%) showed statistical significance compared with placebo Significant weight gain was also more common than weight loss with these drugs and with haloperidol The majority of patients on ziprasidone had no clinically relevant wei